Flushing Financial (FFIC) Trades at $26.26 After Triangle; Shorts at Neurometrix (NURO) Lowered By 15.63%

NeuroMetrix, Inc. (NASDAQ:NURO) Logo

Neurometrix Inc (NASDAQ:NURO) had a decrease of 15.63% in short interest. NURO’s SI was 341,800 shares in April as released by FINRA. Its down 15.63% from 405,100 shares previously. With 50,300 avg volume, 7 days are for Neurometrix Inc (NASDAQ:NURO)’s short sellers to cover NURO’s short positions. The stock decreased 1.41% or $0.02 during the last trading session, reaching $1.4. About 41,589 shares traded. NeuroMetrix, Inc. (NASDAQ:NURO) has declined 71.17% since April 29, 2017 and is downtrending. It has underperformed by 82.72% the S&P500.

Flushing Financial Corporation (FFIC) formed triangle with $27.57 target or 5.00% above today’s $26.26 share price. Flushing Financial Corporation (FFIC) has $749.63M valuation. The stock increased 0.96% or $0.25 during the last trading session, reaching $26.26. About 88,029 shares traded or 0.24% up from the average. Flushing Financial Corporation (NASDAQ:FFIC) has risen 2.88% since April 29, 2017 and is uptrending. It has underperformed by 8.67% the S&P500.

Among 5 analysts covering Flushing Financial (NASDAQ:FFIC), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Flushing Financial had 18 analyst reports since August 25, 2015 according to SRatingsIntel. Piper Jaffray downgraded Flushing Financial Corporation (NASDAQ:FFIC) on Thursday, October 29 to “Neutral” rating. Keefe Bruyette & Woods maintained it with “Hold” rating and $3000 target in Tuesday, August 8 report. The rating was maintained by Keefe Bruyette & Woods with “Hold” on Monday, February 26. The stock has “Hold” rating by Keefe Bruyette & Woods on Tuesday, February 6. The firm has “Hold” rating by Sandler O’Neill given on Thursday, November 30. The rating was upgraded by Sandler O’Neill on Thursday, February 15 to “Buy”. Sandler O’Neill downgraded Flushing Financial Corporation (NASDAQ:FFIC) on Wednesday, August 31 to “Hold” rating. The stock of Flushing Financial Corporation (NASDAQ:FFIC) earned “Hold” rating by Gabelli on Friday, November 11. The firm earned “Sell” rating on Wednesday, September 2 by Zacks. Gabelli upgraded the stock to “Buy” rating in Thursday, April 26 report.

Since February 5, 2018, it had 1 buy, and 1 insider sale for $160,954 activity. $166,380 worth of Flushing Financial Corporation (NASDAQ:FFIC) shares were sold by Obrien Donna M. Shares for $5,426 were bought by Cullen Susan on Thursday, March 1.

Investors sentiment decreased to 1 in 2017 Q4. Its down 0.45, from 1.45 in 2017Q3. It fall, as 9 investors sold Flushing Financial Corporation shares while 31 reduced holdings. 11 funds opened positions while 29 raised stakes. 22.21 million shares or 0.14% less from 22.25 million shares in 2017Q3 were reported. Metropolitan Life Insurance Communications Ny invested in 0% or 9,526 shares. Emerald Mutual Fund Advisers invested in 0.09% or 82,750 shares. Savings Bank Of Montreal Can has invested 0% of its portfolio in Flushing Financial Corporation (NASDAQ:FFIC). Parametric Portfolio Ltd Llc owns 0% invested in Flushing Financial Corporation (NASDAQ:FFIC) for 141,601 shares. Voya Invest Mgmt Ltd Liability has 0% invested in Flushing Financial Corporation (NASDAQ:FFIC) for 16,431 shares. Services Automobile Association has 303,845 shares. Moreover, State Board Of Administration Of Florida Retirement Sys has 0% invested in Flushing Financial Corporation (NASDAQ:FFIC) for 22,573 shares. Geode Cap Management Ltd Co has invested 0% in Flushing Financial Corporation (NASDAQ:FFIC). First Mercantile Tru invested 0.01% of its portfolio in Flushing Financial Corporation (NASDAQ:FFIC). Clarivest Asset Mgmt Ltd reported 0.01% of its portfolio in Flushing Financial Corporation (NASDAQ:FFIC). Putnam Investments Ltd Co has 29,057 shares. Morgan Stanley reported 80,217 shares. Rhumbline Advisers, a Massachusetts-based fund reported 41,911 shares. 123,711 are held by Alphaone Ser Ltd Liability. Denali Ltd Com reported 0% stake.

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company has market cap of $10.30 million. The firm develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. It currently has negative earnings. The Company’s marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; the SENSUS pain therapy device, a prescription neurostimulation device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies.

Among 3 analysts covering Neurometrix (NASDAQ:NURO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurometrix had 6 analyst reports since September 1, 2015 according to SRatingsIntel. H.C. Wainwright maintained the shares of NURO in report on Friday, July 21 with “Buy” rating. Zacks upgraded the stock to “Hold” rating in Tuesday, September 1 report. H.C. Wainwright maintained the shares of NURO in report on Friday, October 20 with “Buy” rating. The firm earned “Buy” rating on Tuesday, June 28 by Rodman & Renshaw. H.C. Wainwright maintained the shares of NURO in report on Thursday, June 15 with “Buy” rating. The stock has “Buy” rating by Maxim Group on Friday, September 11.

Flushing Financial Corporation (NASDAQ:FFIC) Institutional Positions Chart